The company has advanced its lead candidate, resmetirom, a once daily, oral, thyroid hormone receptor (THR) β-selective agonist, into four Phase III clinical trials in NASH. Based on positive results reported to date, Madrigal believes resmetirom has the potential to become the first medication approved for the treatment of patients with NASH.